Orphan Drug Approvals — October 20, 2026

Merck Sharp & Dohme received a label expansion for KEYTRUDA (pembrolizumab), an established immuno-oncology franchise, on 2026-10-16. Indication details, peak sales estimate, and pricing power are NOT_DISCLOSED in the source analysis.

UCB Inc received a label expansion for ZILBRYSQ (zilucoplan) on 2026-10-15, extending the commercial reach of its complement inhibitor. Sales estimate, exclusivity, and market position are NOT_DISCLOSED.

Genentech received a label expansion for ENSPRYNG (satralizumab) on 2026-10-15, adding incremental indication scope to its IL-6 receptor antibody. Commercial metrics are NOT_DISCLOSED.

Label expansions for established biologics can be incremental rather than transformational; without disclosed market-share or indication data, the revenue lift from KEYTRUDA, ZILBRYSQ, and ENSPRYNG cannot be validated against competitive alternatives in their respective markets.

KEYTRUDA is a biologic and faces Medicare negotiation exposure only at roughly year 13 post-licensure; ZILBRYSQ (a synthetic cyclic peptide) and ENSPRYNG (a biologic) carry differing IRA timelines, but the source data does not disclose approval dates to compute exact exposure windows.

KEYTRUDA label expansion extends the franchise's addressable population for Merck Sharp & Dohme; indication-level revenue contribution is NOT_DISCLOSED.

ZILBRYSQ label expansion gives UCB Inc an incremental growth lever for its complement-inhibitor franchise.

ENSPRYNG label expansion adds scope to Genentech's neuroimmunology portfolio within Roche.

All three approvals in this period are label expansions of existing products, with zero NMEs and zero biosimilars, indicating the period's FDA activity was driven by lifecycle management rather than new molecular entities or competitive biosimilar entry.

ZILBRYSQ (complement inhibition) and ENSPRYNG (IL-6 receptor blockade) both represent immunology-adjacent mechanisms receiving label expansions within the same approval window, suggesting continued regulatory momentum for immune-mediated indications.

{"entity" => "KEYTRUDA (pembrolizumab)", "reason" => "Label expansion approved 2026-10-16 for Merck Sharp & Dohme; indication and revenue impact undisclosed in source data.", "trigger" => "Merck quarterly earnings disclosure of the expanded-indication sales contribution and payer formulary updates"}

{"entity" => "ZILBRYSQ (zilucoplan)", "reason" => "Label expansion approved 2026-10-15 for UCB Inc; commercial uptake and pricing undisclosed.", "trigger" => "UCB half-year results and first payer coverage decisions for the expanded label"}

{"entity" => "ENSPRYNG (satralizumab)", "reason" => "Label expansion approved 2026-10-15 for Genentech; competitive positioning undisclosed.", "trigger" => "Roche quarterly update on ENSPRYNG revenue and any competitor label expansion filings in the same indication area"}